Publicacions en què col·labora amb T. Bernal (13)

2024

  1. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670

2023

  1. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

2021

  1. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients

    Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004

2018

  1. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 1, pp. 146-154

2017

  1. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

    Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075

2016

  1. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

    Leukemia & lymphoma, Vol. 57, Núm. 1, pp. 86-91

2014

  1. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

    Cancer, Vol. 120, Núm. 24, pp. 3958-3964

  2. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial

    Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604

2013

  1. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)

    Cancer, Vol. 119, Núm. 9, pp. 1660-1668

2011

  1. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

2010

  1. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group

    Haematologica, Vol. 95, Núm. 4, pp. 589-596

2009

  1. P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia

    Leukemia Research, Vol. 33, Núm. SUPPL. 1

  2. P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

    Leukemia Research, Vol. 33, Núm. SUPPL. 1